Literature DB >> 34978695

Challenges and Recent Advances of Novel Chemical Inhibitors in Medulloblastoma Therapy.

Anand Maurya1, Upendra Kumar Patel1, Jitendra Kumar Yadav1, Virender Pratap Singh1, Alka Agarwal2.   

Abstract

Medulloblastoma is a common term used for the juvenile malignant brain tumor, and its treatment is exciting due to different genetic origins, improper transportation of drug across the blood-brain barrier, and chemo-resistance with various side effects. Currently, medulloblastoma divided into four significant subsections (Wnt, Shh, Group 3, and Group 4) is based on their hereditary modulation and histopathological advancement. In this chapter, we tried to combine several novel chemical therapeutic agents active toward medulloblastoma therapy. All these compounds have potent activity to inhibit the medulloblastoma.
© 2022. The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Brain tumor; IC50 value; Medulloblastoma; Shh group; Wnt group

Mesh：

Substances：

Year:  2022        PMID： 34978695     DOI： 10.1007/978-1-0716-1952-0_13

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN： 1064-3745


  52 in total

Review 1.  Challenges and Recent Advances in Medulloblastoma Therapy.

Authors:  Vinod Kumar; Virender Kumar; Timothy McGuire; Donald W Coulter; John G Sharp; Ram I Mahato
Journal:  Trends Pharmacol Sci       Date:  2017-10-20       Impact factor: 14.819

Review 2.  Medulloblastoma: Molecular understanding, treatment evolution, and new developments.

Authors:  Xiaohua Liu; Chunyong Ding; Wenfu Tan; Ao Zhang
Journal:  Pharmacol Ther       Date:  2020-02-24       Impact factor: 12.310

3.  Single-Cell Transcriptomics in Medulloblastoma Reveals Tumor-Initiating Progenitors and Oncogenic Cascades during Tumorigenesis and Relapse.

Authors:  Liguo Zhang; Xuelian He; Xuezhao Liu; Feng Zhang; L Frank Huang; Andrew S Potter; Lingli Xu; Wenhao Zhou; Tao Zheng; Zaili Luo; Kalen P Berry; Allison Pribnow; Stephanie M Smith; Christine Fuller; Blaise V Jones; Maryam Fouladi; Rachid Drissi; Zeng-Jie Yang; W Clay Gustafson; Marc Remke; Scott L Pomeroy; Emily J Girard; James M Olson; A Sorana Morrissy; Maria C Vladoiu; Jiao Zhang; Weidong Tian; Mei Xin; Michael D Taylor; S Steven Potter; Martine F Roussel; William A Weiss; Q Richard Lu
Journal:  Cancer Cell       Date:  2019-08-29       Impact factor: 31.743

4.  Medulloblastoma: progress over time.

Authors:  Robert I Smee; Janet R Williams; Katie J De-Loyde; Nicola S Meagher; Richard Cohn
Journal:  J Med Imaging Radiat Oncol       Date:  2012-04       Impact factor: 1.735

5.  Treatment Options for Medulloblastoma and CNS Primitive Neuroectodermal Tumor (PNET).

Authors:  Kevin C De Braganca; Roger J Packer
Journal:  Curr Treat Options Neurol       Date:  2013-10       Impact factor: 3.598

6.  Astrocytic trans-Differentiation Completes a Multicellular Paracrine Feedback Loop Required for Medulloblastoma Tumor Growth.

Authors:  Maojin Yao; P Britten Ventura; Ying Jiang; Fausto J Rodriguez; Lixin Wang; Justin S A Perry; Yibo Yang; Kelsey Wahl; Rowena B Crittenden; Mariko L Bennett; Lin Qi; Cong-Cong Gong; Xiao-Nan Li; Ben A Barres; Timothy P Bender; Kodi S Ravichandran; Kevin A Janes; Charles G Eberhart; Hui Zong
Journal:  Cell       Date:  2020-01-23       Impact factor: 41.582

7.  ApoE mimetic peptide targeted nanoparticles carrying a BRD4 inhibitor for treating Medulloblastoma in mice.

Authors:  Qiyue Wang; Virender Kumar; Feng Lin; Bharti Sethi; Donald W Coulter; Timothy R McGuire; Ram I Mahato
Journal:  J Control Release       Date:  2020-05-05       Impact factor: 9.776

8.  NeuroD1 Dictates Tumor Cell Differentiation in Medulloblastoma.

Authors:  Yan Cheng; Shengyou Liao; Gang Xu; Jian Hu; Duancheng Guo; Fang Du; Alejandra Contreras; Kathy Q Cai; Suraj Peri; Yuan Wang; David C Corney; Anne Marie Noronha; Lianne Q Chau; Ginger Zhou; David L Wiest; Alfonso Bellacosa; Robert J Wechsler-Reya; Yi Zhao; Zeng-Jie Yang
Journal:  Cell Rep       Date:  2020-06-23       Impact factor: 9.423

9.  Development of hedgehog pathway inhibitors by epigenetically targeting GLI through BET bromodomain for the treatment of medulloblastoma.

Authors:  Xiaohua Liu; Yu Zhang; Yalei Li; Juan Wang; Huaqian Ding; Wenjing Huang; Chunyong Ding; Hongchun Liu; Wenfu Tan; Ao Zhang
Journal:  Acta Pharm Sin B       Date:  2020-07-21       Impact factor: 11.413

10.  The whole-genome landscape of medulloblastoma subtypes.

Authors:  Paul A Northcott; Ivo Buchhalter; A Sorana Morrissy; Volker Hovestadt; Joachim Weischenfeldt; Tobias Ehrenberger; Susanne Gröbner; Maia Segura-Wang; Thomas Zichner; Vasilisa A Rudneva; Hans-Jörg Warnatz; Nikos Sidiropoulos; Aaron H Phillips; Steven Schumacher; Kortine Kleinheinz; Sebastian M Waszak; Serap Erkek; David T W Jones; Barbara C Worst; Marcel Kool; Marc Zapatka; Natalie Jäger; Lukas Chavez; Barbara Hutter; Matthias Bieg; Nagarajan Paramasivam; Michael Heinold; Zuguang Gu; Naveed Ishaque; Christina Jäger-Schmidt; Charles D Imbusch; Alke Jugold; Daniel Hübschmann; Thomas Risch; Vyacheslav Amstislavskiy; Francisco German Rodriguez Gonzalez; Ursula D Weber; Stephan Wolf; Giles W Robinson; Xin Zhou; Gang Wu; David Finkelstein; Yanling Liu; Florence M G Cavalli; Betty Luu; Vijay Ramaswamy; Xiaochong Wu; Jan Koster; Marina Ryzhova; Yoon-Jae Cho; Scott L Pomeroy; Christel Herold-Mende; Martin Schuhmann; Martin Ebinger; Linda M Liau; Jaume Mora; Roger E McLendon; Nada Jabado; Toshihiro Kumabe; Eric Chuah; Yussanne Ma; Richard A Moore; Andrew J Mungall; Karen L Mungall; Nina Thiessen; Kane Tse; Tina Wong; Steven J M Jones; Olaf Witt; Till Milde; Andreas Von Deimling; David Capper; Andrey Korshunov; Marie-Laure Yaspo; Richard Kriwacki; Amar Gajjar; Jinghui Zhang; Rameen Beroukhim; Ernest Fraenkel; Jan O Korbel; Benedikt Brors; Matthias Schlesner; Roland Eils; Marco A Marra; Stefan M Pfister; Michael D Taylor; Peter Lichter
Journal:  Nature       Date:  2017-07-19       Impact factor: 49.962
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.